Medical service provider Field Medical has secured a $35 million investment to further develop its FieldForce platform.
**Field Medical Advances Pulsed Field Ablation Technology for Ventricular Tachycardia Treatment**
In a significant development for the cardiology industry, Field Medical, Inc. is pushing the boundaries of pulsed field ablation (PFA) technology to address ventricular tachycardia (VT), a life-threatening heart condition.
**Innovative FieldForce Ablation System**
At the heart of Field Medical's innovation is the FieldForce Ablation System, a next-generation PFA technology designed specifically for transmural lesion creation in VT treatment. The system's contact force, focal PFA catheter enables instantaneous ablation, a crucial factor in treating VT effectively[1][2][3].
**Funding and Clinical Trials**
Recently, Field Medical secured a $35 million oversubscribed Series B funding round to further develop the FieldForce system and initiate its pivotal VERITAS trial. This clinical trial aims to assess the efficacy and safety of their technology in treating VT, a condition that remains underpenetrated in electrophysiology despite strong clinical demand[1][2].
**Recognition from Regulatory Bodies**
In 2024, the FieldForce Ablation System received Breakthrough Device Designation from the FDA for its VT indication and was selected for the FDA TAP Pilot Program. These recognitions highlight the system's potential to revolutionize VT treatment[1].
**New Leadership and Investment**
Ben Cannon, Founding Partner of Cue Growth, has joined Field Medical's Board of Directors, bringing deep experience in scaling growth-stage companies and institutional governance expertise. Mark Wisniewski, CFO of Enterra Medical, has also joined as the chairperson[4]. Existing strategic investors also participated in the financing round, which was co-led by BioStar Capital and Cue Growth[5].
Marlou Janssen, with extensive experience in the cardiology and medtech industries, has been appointed as a Board Member at Field Medical. Alexei Mlodinow, with a track record in medtech innovation and multiple exits, has also joined the Board[6].
**Vision for the Future**
Steven Mickelsen, MD, founder and CEO of Field Medical, emphasizes that ventricular tachycardia is among the most underpenetrated segments in electrophysiology. He believes that Field Medical's next-generation therapy, built for speed, precision, and real clinical progress, could redefine the landscape of VT care for high-risk patients[7].
Louis Cannon, MD, founder and senior managing director of BioStar Capital, expressed excitement about Field Medical's transformative technology tackling one of the most difficult and under-addressed challenges in cardiology[5].
The updates to Field Medical's Board of Directors are in alignment with its accelerated growth trajectory, as the company continues to redefine cardiac ablation with next-generation pulsed field ablation (PFA) technology.
[1] Field Medical, Inc. (2025). Press Release: Field Medical Secures Oversubscribed Series B Financing. [2] Field Medical, Inc. (2025). Press Release: Field Medical Receives Breakthrough Device Designation from the FDA. [3] Field Medical, Inc. (2025). Press Release: Field Medical to Present at the 2025 Heart Rhythm Society Meeting. [4] Field Medical, Inc. (2025). Press Release: Ben Cannon Joins Field Medical's Board of Directors. [5] BioStar Capital (2025). Press Release: BioStar Capital Co-Leads Series B Financing in Field Medical, Inc. [6] Field Medical, Inc. (2025). Press Release: Alexei Mlodinow and Marlou Janssen Join Field Medical's Board of Directors. [7] Field Medical, Inc. (2025). Press Release: Steven Mickelsen Named Founder and CEO of Field Medical, Inc.
Science plays a crucial role in addressing medical-conditions, such as ventricular tachycardia, as the cardiovascular health of individuals is significantly impacted. The recent breakthroughs in pulsed field ablation technology by Field Medical, Inc., through their innovative FieldForce Ablation System, could revolutionize the health-and-wellness sector by offering effective treatments for this life-threatening heart condition.
